SATELLITE SCIENTIFIC WORKSHOP
REAL WORLD EVIDENCE ON THE IMPACT OF MEDICINES
15 JANUARY 2019
13:30-18:00
- Measures of impact of medicines in the real life: are methods adapted?
- How to accelerate access to important medicines by the right mix of pre-marketing / post-marketing studies?
- How to do pharmacoepidemiologic research with a real clinical and public health impact?
- What research is useful for Decision-Making?
- UK, France & Italy coverage with evidence development policies: what went wrong (and well)?
- Can RCT + Modelling Replace Observational Studies?

SYMPOSIUM
SCIENCE, PATIENTS AND THE POLITICS OF ACCESS TO HIGH VALUE MEDICINES
16 JANUARY 2019
09:00-18:00
- The International, the European, the Central European challenges at a time of change
- Is Brexit going to complicate or simplify the issues in Europe?
- Are present HTA models adapted to high value innovation?
- At what cost can we afford innovations? Will new economic models solve it all?
- Industry approach to high value medicines: Thinking Globally and Acting Locally? Or else?
- Access to High Value Medicines: a Human Right?
- Does the American “Patient First” call apply to Europe?
- Rare diseases, cancer: same struggle?

Registration and more information at:
www.accessibility-symposium.org
ACCESSIBILITY & IMPACT OF HIGH VALUE MEDICINES
SCIENCE, PATIENTS, POLITICS

SYMPOSIUM CO-CHAIRS

PROF. PETER PIOT
Director, London School of Hygiene & Tropical Medicine, Former Head, UNAIDS

PROF. LUCIEN ABENHAIM
Hon. Prof. LSHTM LA Risk Research Fmr Board Member, WHO

SPEAKERS AND PANELISTS
- HEALTH AUTHORITIES FROM NICE, HAS, G-BA, CEE COUNTRIES, THE EUROPEAN COMMISSION AND WHO
- PATIENT ADVOCATES
- INDUSTRY DECISION-MAKERS
- LEADERS IN HEALTH LAW & GOVERNANCE, PHARMACOECONOMICS & PHARMACO-EPIDEMIOLOGY

REAL WORLD EVIDENCE WORKSHOP 15 JANUARY 2019

SYMPOSIUM 16 JANUARY 2019

HEALTH AUTHORITIES

PROF. DOMINIQUE LE GULUDEC
President, Higher Health Authority (HAS), France

SIR ANDREW DILLON
Chief Executive, NICE, UK

DR. ANDRZEJ RYS
Director for Health Systems, Medical, Prod. & Innovation European Commission.

DR. SARAH GARNER
Coordinator Innovation, Access and Use, Essential Med. & Health Products, WHO

DR. MIRJANA HUIC
Agency Quality and Accreditation in Health Care and Social Welfare Croatia

DR. ANTJE BEHRING
Acting Head of Pharmaceuticals Department (AMNOG), Federal Joint Committee (G-BA).

INDUSTRY DECISION MAKERS

PROF. MARTIN MCKEE
London School of Hygiene & Tropical Medicine, UK

PROF. RON AKEHURST
University of Sheffield, UK

PROF. GORIK OOMS
Global Health Law & Governance, London School of Hygiene & Tropical Medicine

YANN LE CAM
Chief Executive, EURORDIS, Rare Diseases Europe

Keynote Speaker

PROF. STEPHEN EVANS
London School of Hygiene & Tropical Medicine, UK

PROF. GÉRARD DE POUVOYRILLE
ESSEC Business School, France

PROF. LIAM SMEETH
London School of Hygiene & Tropical Medicine, UK

PHARMACOECONOMISTS & EXPERTS

PROF. PATRICE MATHABABA
Group Head Global Health & Corp. Responsibility, Novartis

DR. ANNALISA JENKINS
CEO PlaqueTec

DR. THOMAS LYNCH
CSO & Exec VP R&D, IMS

DR. MICHAEL DEVOY
CMO Bayer HealthCare

DR. ROB SCOTT
CMO & VP Development AteVe

DR. JENS GRUEGER
SVP Head of Global Access, Roche

DR. CLAUS RUNGE
Market Access Bayer Health Care

Registration and more information at:
www.accessibility-symposium.org
PROGRAMME OF THE SATELLITE WORKSHOP
EVIDENCES OF THE IMPACT OF ACCESS

13:00 Registration, Tea and Coffee

Workshop Chair: Prof. Stephen Evans, LSHTM
Objectives of the Workshop: Prof. Lucien Abenhaim, LSHTM

First Part: Relevant Methods for Access Impact Assessment

13:30 How can observational studies reproduce causality assessment – Results of a FDA-Harvard Research Programme
Prof. Sebastian Schneeweiss, Harvard Medical School & T.C. Chan School of Public Health

Can impact assessment be reliably predicted?
Dr. Billy Amzal, X-Ponts & Analytica Certara

Panel discussion: Introduction by Bernard Begaud (University of Bordeaux)
Causality, biases and decision: when is enough enough?

15:30 Break

Second Part: Case-Studies on Public Health Impact of Recent Medicines & Vaccines

15:45 Chair: Prof. Liam Smeeth, Bernard Begaud (University of Bordeaux)
Results of research on the public health impact of medicines

Impact of Maternal Immunization and Monitoring of Safety
Prof. Miriam Sturkenboom* Utrecht Medical Center, The Netherlands

Vaccines and auto-immune disorders: review and results
Prof. Lamiae Grimaldi, University of Paris-Versailles SQY

Vaccines: From Perception to Action
Prof. Heidi Larson, London School of Hygiene & Tropical Medicine

Observational studies and regulatory decisions: ANSM experience
Prof Mahmoud Zureik (Université Versailles St-Quentin & Agence Nationale de Sécurité des Médicaments (ANSM), France

17:00 Panel: Is a Scientific Forum on the Public Health Impact Assessment of Medicines Needed?
All Workshop Attendees

17:45 Conclusions and Recommendations for the Policy Session

18:00 Workshop Closure

LIMITED SEATS ARE AVAILABLE AT THE WORKSHOP

Registration and more information at:
www.accessibility-symposium.org

SEE PROGRAMME OF THE SYMPOSIUM
POLICY SESSION
SESSION 1: EUROPE AMONGST WORLD CHALLENGES

9:00 Welcome, Objectives & Orientations  
Prof. Lucien Abenhaim, LSHTM & LARR, Symposium Co-Chair  
• The Road to Access  
Prof. Peter Piot, Director, London School of Hygiene & Tropical Medicine Symposium Co-Chair  
• Worldwide Situation of Access to Medicines  
Dr. Sarah Garner, Coordinator Innovation, Access & Use, Essential Medicines, WHO  
• Access to High Value Medicines: European Union Policy at a Time of Change  
Dr. Andrzej Rys, Director, Health Systems, European Commission  
• Access to High Value Medicines in the UK at a Time of Change  
Sir Andrew Dillon, Chief Executive, NICE  
• For a new policy on innovative Medicines in Europe: Recent Report to EC  
Prof. Martin McKee, LSHTM  

10:40 Morning Break  

11:00 Keynote Address: Access to Medicines: Industry Proposals at a Time of Change  
Dr. Stefan Oschmann, President, EFPIA (European Federation of Pharmaceutical Industry Associations) and CEO, Merck Group  

Panel discussion: Brexit and World Challenges  
All speakers of the morning session and Dr. Patrice Matchaba (Novartis)  

12:30 Lunch  

13:45 SESSION 2: THE SCIENCES OF ACCESS IN EUROPE  
• HAS Assessment Methodology: What’s New?  
Prof. Dominique Le Guludec, HAS (Haute Autorité de Santé, France)  
• NICE Highly Specialized Technologies Committee’s Methods  
Prof. Ron Akehurst, Health Economist, ScHARR, University of Sheffield  
• Access to High Value Medicine in Germany: The G-BA Method Revisited  
Dr. Antje Behring, Acting Head of Pharmaceuticals Department, AMNOG.  
• Making High Value Medicines Available in the CEE: a Survey of Multiple CEE Countries  
Dr. Mirjana Huic, Agency Quality and Accreditation in Health Care and Social Welfare Croatia  
• HTA & Pricing: Is There One Solution to the Challenge?  
Prof. Gerard de Pouvourville, ESSEC Business School  

Prof. Stephen Evans (LSHTM) & Prof. Sebastian Schneeweiss (Harvard Medical School)  

15:30 Panel discussion: Are Solutions for Access More Converging or Diverging in Europe?  
All speakers of the session and Dr. Rob Scott (AbbVie) & Dr. Michael Devoy (Bayer)  

16:00 Afternoon Break  

SESSION 3: PANEL CASE STUDIES: HURDLES & SOLUTIONS FOR ACCESS IN PRACTICE  

16:15  
• Access to Rare Diseases Medicines. Yann Le Cam (EURORDIS)  
• Evaluation of New Cancer Treatments for Access.  
• The ‘American Patients First’ Blueprint and Europe. Dr. Jens Grueger (Roche)  
• Development of accessible tests and devices. Dr. Annalisa Jenkins (PlaqueTec)  

Panel discussion: General Policies or Myriad of Problem-Specific Solutions?  
All Speakers of the Panel and Dr. Thomas Lynch (BMS) and Dr. Claus Runge (Bayer),  

17:30 Closing Conference: Global Health Governance and Access to Medicines as a Human Right  
Prof. Gorik Ooms, London School of Hygiene & Tropical Medicine  

18:00 Symposium Closure and Networking Reception
The workshop will be held at the London School of Hygiene & Tropical Medicine and allows limited seating (40)

The SYMPOSIUM is at the LONDON SAINT-PANCras RENAISSANCE HOTEL

MORE INFORMATION AND REGISTRATION AT: www.accessibility-symposium.org

FEES FOR THE SYMPOSIUM

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGULAR FEES</td>
<td>£499 + VAT</td>
<td></td>
</tr>
<tr>
<td>ACADEMIA &amp; PUBLIC AGENCIES</td>
<td>£199 + VAT</td>
<td></td>
</tr>
<tr>
<td>CONSULTING &amp; SERVICE COMPANIES</td>
<td>£1200 + VAT</td>
<td></td>
</tr>
</tbody>
</table>

REGISTRATION TO THE WORKSHOP IS UPON REQUEST

Fees include welcome tea & coffee, breaks, lunch.

Fees do not include accommodations. Special rates are available for the Saint-Pancras Renaissance Hotel. A list of nearby hotels with varying rates is available upon request.

No profits are drawn from the Workshop and Symposium.

Registration and more information at:
www.accessibility-symposium.org